Paul Stead, a former executive at GlaxoSmithKline Plc, has joined Adaptimmune Therapeutics Plc as head of business development to help progress the company’s T cell receptor products in oncology. Dr Stead joins Adaptimmune from Inovio Pharmaceuticals Inc. Before that, he was an executive at Nimbus Therapeutics LLC. He holds a bachelor of science degree and PhD in pharmaceutical sciences from Bath and Nottingham Universities in the UK, respectively.
Adaptimmune announced the appointment on 4 January 2018.
Copyright 2018 Evernow Publishing Ltd